Zenas BioPharma, Inc.
ZB021
Countdown
177days
Phase 1 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 1 trial results for ZB021 in its lead indication are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Zenas expects to initiate Phase 1 clinical development for ZB021 in the second quarter of 2026 and to report initial clinical data by year-end 2026”